Amphastar Pharmaceuticals, Inc. Inventory Write-down
Amphastar Pharmaceuticals, Inc. (AMPH) reported Inventory Write-down of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. inventory write-down for the quarter ending 2026-06-30 was $2.70M, a 0.00% change year-over-year.
- Amphastar Pharmaceuticals, Inc. inventory write-down for the quarter ending 2026-03-31 was $2.20M, a 1000.00% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. inventory write-down for the quarter ending 2025-12-31 was $1.80M, a 53.85% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. inventory write-down for the quarter ending 2025-09-30 was $1.30M, a 44.44% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. inventory write-down for fiscal 2025 was $6.00M, a 57.14% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. inventory write-down for fiscal 2024 was $14.00M, a 25.53% decline from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. inventory write-down for fiscal 2023 was $18.80M, a 9.30% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. inventory write-down for fiscal 2022 was $17.20M, a 30.08% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $4.90M 10-Q · filed 2026-08-06 | $6.70M derived: sum of 3 quarters · filed 2026-08-06 | $8.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-07 | $4.00M derived: sum of 2 quarters · filed 2026-05-07 | $5.30M derived: sum of 3 quarters · filed 2026-05-07 | $8.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.10M derived: sum of 2 quarters · filed 2026-02-26 | $5.80M derived: sum of 3 quarters · filed 2026-08-06 | $6.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.30M 10-Q · filed 2025-11-06 | $4.00M derived: sum of 2 quarters · filed 2026-08-06 | $4.20M 10-Q · filed 2025-11-06 | $8.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.70M 10-Q · filed 2026-08-06 | $2.90M 10-Q · filed 2026-08-06 | $6.80M derived: sum of 3 quarters · filed 2026-08-06 | $7.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | $4.10M derived: sum of 2 quarters · filed 2026-05-07 | $5.00M derived: sum of 3 quarters · filed 2026-05-07 | $8.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.80M derived: sum of 2 quarters · filed 2026-02-26 | $8.30M derived: sum of 3 quarters · filed 2026-02-26 | $14.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-06 | $4.40M derived: sum of 2 quarters · filed 2025-11-06 | $10.10M 10-Q · filed 2025-11-06 | $19.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.50M 10-Q · filed 2025-08-07 | $9.20M 10-Q · filed 2025-08-07 | $18.40M derived: sum of 3 quarters · filed 2026-02-26 | $18.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.70M 10-Q · filed 2025-05-08 | $14.90M derived: sum of 2 quarters · filed 2026-02-26 | $14.90M derived: sum of 3 quarters · filed 2026-02-26 | $23.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.20M derived: sum of 2 quarters · filed 2026-02-26 | $17.50M derived: sum of 3 quarters · filed 2026-02-26 | $18.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $8.30M derived: sum of 2 quarters · filed 2024-11-07 | $9.60M 10-Q · filed 2024-11-07 | $13.30M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $8.30M 10-Q · filed 2024-08-09 | $10.20M 10-Q · filed 2024-08-09 | $13.30M derived: sum of 3 quarters · filed 2025-03-03 | $18.80M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.90M 10-Q · filed 2024-05-10 | $5.00M derived: sum of 2 quarters · filed 2025-03-03 | $10.50M derived: sum of 3 quarters · filed 2025-03-03 | $11.10M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.60M derived: sum of 2 quarters · filed 2025-03-03 | $9.20M derived: sum of 3 quarters · filed 2025-03-03 | $17.20M 10-K · filed 2025-03-03 |
| 2022-09-30 | $5.50M 10-Q · filed 2023-11-08 | $6.10M derived: sum of 2 quarters · filed 2023-11-08 | $14.10M 10-Q · filed 2023-11-08 | $21.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-09 | $8.60M 10-Q · filed 2023-08-09 | $16.20M derived: sum of 3 quarters · filed 2024-02-29 | $22.30M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $8.00M 10-Q · filed 2023-05-09 | $15.60M derived: sum of 2 quarters · filed 2024-02-29 | $21.70M derived: sum of 3 quarters · filed 2024-02-29 | $23.10M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $13.70M derived: sum of 2 quarters · filed 2024-02-29 | $15.10M derived: sum of 3 quarters · filed 2024-02-29 | $24.60M 10-K · filed 2024-02-29 |
| 2021-09-30 | $6.10M 10-Q · filed 2021-11-09 | $7.50M derived: sum of 2 quarters · filed 2021-11-09 | $17.00M 10-Q · filed 2021-11-09 | $18.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.40M 10-Q · filed 2021-08-09 | $10.90M 10-Q · filed 2021-08-09 | $12.10M derived: sum of 3 quarters · filed 2023-03-01 | $14.60M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $9.50M 10-Q · filed 2022-05-10 | $10.70M derived: sum of 2 quarters · filed 2023-03-01 | $13.20M derived: sum of 3 quarters · filed 2023-03-01 | $21.30M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.70M derived: sum of 2 quarters · filed 2023-03-01 | $11.80M derived: sum of 3 quarters · filed 2023-03-01 | $13.90M 10-K · filed 2023-03-01 |
| 2020-09-30 | $2.50M 10-Q · filed 2020-11-06 | $10.60M derived: sum of 2 quarters · filed 2020-11-06 | $12.70M 10-Q · filed 2020-11-06 | $16.00M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $8.10M 10-Q · filed 2020-08-07 | $10.20M 10-Q · filed 2020-08-07 | $13.50M derived: sum of 3 quarters · filed 2022-03-11 | $13.90M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $2.10M 10-Q · filed 2021-05-07 | $5.40M derived: sum of 2 quarters · filed 2022-03-11 | $5.80M derived: sum of 3 quarters · filed 2022-03-11 | $8.30M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $3.70M derived: sum of 2 quarters · filed 2022-03-11 | $6.20M derived: sum of 3 quarters · filed 2022-03-11 | $9.40M 10-K · filed 2022-03-11 |
| 2019-09-30 | $400.00K 10-Q · filed 2019-11-08 | $2.90M derived: sum of 2 quarters · filed 2019-11-08 | $6.10M 10-Q · filed 2019-11-08 | $12.40M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $2.50M 10-Q · filed 2019-08-09 | $5.70M 10-Q · filed 2019-08-09 | $12.00M derived: sum of 3 quarters · filed 2021-03-15 | $15.50M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $3.20M 10-Q · filed 2020-05-11 | $9.50M derived: sum of 2 quarters · filed 2021-03-15 | $13.00M derived: sum of 3 quarters · filed 2021-03-15 | $14.20M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $9.80M derived: sum of 2 quarters · filed 2021-03-15 | $11.00M derived: sum of 3 quarters · filed 2021-03-15 | $12.90M 10-K · filed 2021-03-15 |
| 2018-09-30 | $3.50M 10-Q · filed 2019-11-08 | $4.70M derived: sum of 2 quarters · filed 2019-11-08 | $6.60M 10-Q · filed 2019-11-08 | $7.80M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $1.20M 10-Q · filed 2019-08-09 | $3.10M 10-Q · filed 2019-08-09 | $4.30M derived: sum of 3 quarters · filed 2020-03-16 | $6.50M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $1.90M 10-Q · filed 2019-05-10 | $3.10M derived: sum of 2 quarters · filed 2020-03-16 | $5.30M derived: sum of 3 quarters · filed 2020-03-16 | $10.00M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.40M derived: sum of 2 quarters · filed 2020-03-16 | $8.10M derived: sum of 3 quarters · filed 2020-03-16 | $8.50M 10-K · filed 2020-03-16 |
| 2017-09-30 | $2.20M 10-Q · filed 2018-11-09 | $6.90M derived: sum of 2 quarters · filed 2018-11-09 | $7.30M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $4.70M 10-Q · filed 2018-08-09 | $5.10M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $400.00K 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $7.30M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |